Analysis and Evaluation of Smoking Treatment With Cytisine
Analysis and Evaluation of Smoking Treatment With Cytisine: Retrospective Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Maria Papale, Doctor
- Phone Number: +39 0652666903
- Email: maria.papale@ifo.it
Study Locations
-
-
-
Rome, Italy, 00144
- Recruiting
- "Regina Elena" National Cancer Institute
-
Contact:
- Maria Papale, Doctor
- Phone Number: +39 0652666903
- Email: maria.papale@ifo.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients aged > 18 years;
- patients suffering from moderate or severe tobacco use disorder;
- prescription of pharmacological therapy with Cytisine;
- patients returned to the 1st check-up on schedule;
Exclusion Criteria:
- Patients with contraindications to taking Cytisine and partial receptor agonists nicotinic cholinergics;
- Patients undergoing pharmacological or physical treatment for neoplastic pathology;
- Pregnant or breastfeeding women;
- Patients for whom specific information for objective assessments is not available;
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with moderate or severe tobacco use disorder.
Patients hospitalized at the IRE anti-smoking center, National Cancer Institute "Regina Elena", suffering from moderate or severe tobacco use disorder, who are prescribed pharmacological therapy with Cytisine 1.5 mg.
|
Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Therapeutic adherence
Time Frame: 3 months
|
Evaluation of adherence to the prescribed drug therapy i.e.
Cytisine 1.5 mg
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the effectiveness of the therapy.
Time Frame: 3 months
|
Evaluation of the effectiveness of the therapy with the achievement of smoking cessation subsequent checks occurred after clinical evaluation and measurement of the monoxide value exhaled carbon.
|
3 months
|
|
Evaluation of therapeutic adherence in relation to motivation.
Time Frame: 3 months
|
Evaluation of adherence to Cytisine therapy in relation to the patient's motivation measured with the Mondor motivational test.
|
3 months
|
|
Assessment of adherence in relation to the dependency score physics.
Time Frame: 3 months
|
Evaluation of adherence to Cytisine therapy in relation to the addiction score physical measured with the Nicotine dependence questionnaire or Fagerström test.
|
3 months
|
|
Safety and Tolerability assessment.
Time Frame: 3 months
|
Safety and Tolerability assessment describing any adverse reactions related to the intake of Cytisine.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RS104/IRE/24
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.